Quantifying survival disparities among children diagnosed with cancer on a global scale
Menée à partir d'un modèle de microsimulation, cette étude estime la survie nette à 5 ans chez des enfants atteints d'un cancer dans 200 pays et territoires, et analyse les facteurs associés
The remarkable increase in 5-year net survival for children diagnosed with cancer from nearly 0% to 80% over the past six decades highlights notable success in cancer treatment and research. These improvements have been the most striking in high-income countries such as the UK. Although it is largely accepted that low-income and middle-income countries have not achieved these gains, the magnitude of the overall survival gap is difficult to ascertain, largely due to the absence of population-based cancer registries in many of these countries. Thus far, the best available global data were available from the CONCORD programme, which across three studies (or cycles) compiled individual records from more than 300 population-based registries in over 70 countries. In fact, CONCORD-3 covered almost 1 billion people worldwide. However, this massive effort only published survival estimates for a subset of childhood cancers: acute lymphoblastic leukaemia, acute myeloid leukaemia, lymphomas (as a group), and brain tumours. Although these diseases are the three most common childhood cancers, overall, they comprise approximately 60% of diagnoses. Therefore, data from the CONCORD programme is insufficient to make inferences about survival for a notable proportion of other childhood cancers.